TMEM9B Activators

TMEM86B can influence the protein's activity through various intracellular signaling pathways primarily involving the modulation of cyclic adenosine monophosphate (cAMP). Forskolin is known to directly activate adenylate cyclase, which catalyzes the conversion of ATP to cAMP. Elevated cAMP levels can lead to the activation of protein kinase A (PKA), a kinase that phosphorylates numerous cellular targets, potentially including TMEM86B. Similarly, the beta-adrenergic agonist Isoproterenol can elevate intracellular cAMP, again promoting PKA signaling that may lead to the phosphorylation and consequent activation of TMEM86B. IBMX, by inhibiting phosphodiesterases that degrade cAMP, sustains the signaling that can result in the activation of TMEM86B through continued PKA activity. Furthermore, PGE2 stimulates its receptors to increase cAMP levels, which, through PKA, can activate TMEM86B.

Chlorophenylthio-cAMP, as a stable cAMP analog, resists degradation and maintains PKA activity, which supports TMEM86B activation. Rolipram, BAY 60-7550, and Vinpocetine, as selective inhibitors of PDE4, PDE2, and PDE1 respectively, prevent cAMP breakdown and facilitate PKA-mediated TMEM86B activation. Zaprinast, another PDE inhibitor, specifically targets PDE5 and can enhance cAMP levels, providing further opportunity for PKA to activate TMEM86B. Terbutaline and Albuterol, both beta-adrenergic agonists, induce cAMP production, leading to PKA activation. PKA then proceeds to phosphorylate various substrates in the cell, potentially including TMEM86B, to influence its activity state. Each of these chemicals, through their actions on cAMP levels and PKA signaling, can contribute to the functional activation of TMEM86B by promoting its phosphorylation state, which is often a regulatory mechanism for protein activation.